Hepatitis B virus (HBV) is a noncytopathic, enveloped virus that causes acute and chronic hepatitis and hepatocellular carcinoma (7). The cellular immune response to HBV antigens is thought to play a critical role in the pathogenesis of the disease and in clearance of the infection. We have previously reported that adoptively transferred HBV-specific cytotoxic T lymphocytes (CTLs) abolish HBV replication and gene expression in the liver of HBV transgenic mice (19). This effect is achieved by two distinct mechanisms following antigen recognition: first, the CTLs kill a small fraction of the hepatocytes; and second, they secrete gamma interferon (IFN-γ) and tumor necrosis factor alpha (TNF-α), which noncytolytically interrupt the viral life cycle in all of the hepatocytes. Based on these observations, we have suggested that this cytokine-mediated curative CTL function may contribute substantially to viral clearance during HBV infection (17).

If this argument is correct, HBV should be susceptible to control by nonspecific stimuli that induce antiviral cytokines in infected tissues. Indeed, we have recently demonstrated that HBV replication can be abolished in these animals during lymphocytic choriomeningitis virus infection (16) and following the administration of interleukin-12 (5). The present study was undertaken to determine if other viruses, including murine cytomegalovirus (MCMV) and a replication-defective recombinant adenovirus developed to deliver foreign genes to the liver, can induce sufficient quantities of these cytokines to suppress HBV replication. These viruses were chosen because they are hepatotropic (43, 47) and because CD8+ CTLs and natural killer (NK) cells that produce large amounts of these cytokines play a pivotal role in resolving their respective infections (27, 32, 54).

**MATERIALS AND METHODS**

**HBV transgenic mice.** The HBV transgenic mouse lineage 1.3.32 (official designation, Tg[HBV 1.3 genome][Chi32]) used in this study has been described previously (21). These mice replicate HBV at high levels in the liver and kidney without any evidence of cytopathology. Lineage 1.3.32 was expanded by repetitive backcrossing against the C57BL/6 parental strain and then bred one generation against BALB/c mice to produce the F1 hybrids used in all experiments described here. Mice matched for age (6 to 10 weeks), sex (male), and levels of hepatitis B surface antigen (HBsAg) in the serum (determined by using a commercially available kit from Abbott Laboratories, Abbott Park, Ill.) were used.

**Adenovirus infection.** A recombinant, replication-deficient adenovirus designated Ad.CBlaZ (28) was kindly provided by James D. Darnell, Jr., of the Pennsylvania Medical Center, Philadelphia. This virus is based on human adenovirus type 5, in which sequences spanning the E1a and E1b genes (from 1.0 to 9.2 map units) were deleted and replaced with a minigene cassette of the *Escherichia coli lacZ* gene, encoding β-galactosidase, driven by a cytomegalovirus-enhanced β-actin promoter. It also contains a small deletion in the E3 region (150 bp within the 14.6-kb DNA). Mice infected with this virus develop a strong CD8+ CTL response to adenovirus proteins, resulting in hepatitis (54, 56).

**MCMV infection.** The Smith strain of MCMV (American Type Culture Collection [ATCC] VR-194, ATCC, Rockville, Md.) was used in this study. Acute infection with MCMV leads to widespread growth of the virus in virtually all organ systems (36) and can also result in severe hepatitis (43). A stock of MCMV was prepared as a 10% (wt/vol) homogenate of the submaxillary salivary glands from infected BALB/c mice (41). These mice, at 21 days of age, were injected intraperitoneally with 1.0 × 10⁶ PFU of tissue culture-passaged virus (grown in and titrated on NIH 3T3 cells [ATCC CRL1658]), and their salivary glands were harvested, pooled, and homogenized 14 days later. This salivary gland-passaged MCMV stock was titered by standard plaque assay on NIH 3T3 cells. Mice were infected intraperitoneally with various doses of MCMV diluted in 200 μl of sterile 0.9% NaCl (saline) solution via the tail vein. Control mice were injected with the same volume of saline. Animals were sacrificed at multiple time points following infection, and their livers and kidneys were harvested for histological, immunohistochemical, and histochemical analyses (see below), or they were snap frozen in liquid nitrogen and stored at −80°C for subsequent DNA and RNA analyses.

**Tissue DNA and RNA analyses.** Frozen liver (left lobe) and kidney tissues were mechanically pulverized under liquid nitrogen, and total genomic DNA and RNA were isolated for Southern and Northern blot analyses exactly as previously described (21). Nylon membranes were analyzed for HBV DNA, HBV RNA, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and β-2′-oligoadényl-
RESULTS

Adenovirus infection inhibits HBV replication and cytoplasmic nucleocapsid content in the livers of HBV transgenic mice. The replication-defective recombinant adenovirus (Ad.CBlacZ) used in this study is capable of infecting murine hepatocytes and expressing the introduced transgene (in this case the E. coli lacZ gene), but it does not replicate in these cells (28). Expression of β-galactosidase and adenoviral proteins in the infected hepatocytes triggers a specific cellular immune response which causes a prolonged necroinflammatory liver disease and eventually clears the infection (54–56, 58–60).

Eighteen age-, sex-, and serum HBsAg-matched transgenic mice were infected intravenously (via the lateral tail vein) with 5 × 10^9, 1.5 × 10^9, or 5.0 × 10^9 PFU of Ad.CBlacZ, and groups of three mice were sacrificed on days 1, 3, 7, 14, 24, and 42 after infection. The number of lacZ-positive hepatocytes detectable corresponded to the infectious inoculum and was time dependent (shown at the bottom of Fig. 1), indicating that all animals were successfully infected. These animals developed a dose-dependent necroinflammatory liver disease that was detectable histologically (Fig. 2C) and biochemically as elevated sALT activity (Fig. 1) starting 3 to 7 days after inoculation and lasting 1 to 6 weeks, until lacZ-positive hepatocytes were no longer detectable. The severity and duration of the liver disease was dependent on the dose of infecting virus, as illustrated at the bottom of Fig. 1 (the upper limit of normal is approximately 50 U/liter).

Southern blot analysis was performed to compare the levels of hepatic HBV replicative DNA forms in adenovirus-infected mice and in age- and sex-matched transgenic mice that had been injected with saline. At all three doses of Ad.CBlacZ, HBV DNA disappeared from the liver within 1 day of infection (Fig. 1B) and before the onset of liver disease, indicated by normal sALT values shown at the bottom of Fig. 1 and normal liver histology (not shown). These results indicate that HBV replication was not inhibited as a consequence of hepatocellular regeneration because there was no evidence of liver cell injury or turnover in the liver at this time point. Importantly, the antiviral effect coincided with the induction of 2′-OAS in normal livers (54), although traces of TNF-α mRNA were induced by the highest dose of adenovirus at the 1-day time point.

At the lower doses of Ad.CBlacZ, HBV replication...
reappeared on day 3 postinfection, coinciding with the disappearance of 2′5′-OAS mRNA in the liver and in the absence of the T-cell, IFN-γ, and TNF-α mRNAs (Fig. 1). At these doses, HBV replication disappeared a second time by day 7 postinfection, coinciding with the reinduction of 2′5′-OAS mRNA and the appearance of CD3, CD4, CD8, IFN-γ, and TNF-α mRNAs (Fig. 1). Corresponding with the influx of T cells, sALT activity was clearly elevated on day 7 (Fig. 1), reflecting the onset of an inflammatory liver disease which was also detectable histologically (Fig. 2C), as previously described (50, 54–56, 58–60). The low-dose Ad.CBlacZ infection was cleared by day 14, reflected by the disappearance of lacZ-positive hepatocytes, normalization of sALT activity, and the disappearance of T-cell and cytokine markers (Fig. 1). Corresponding with these events, HBV replication resumed at this time (Fig. 1). The liver disease was more prolonged and severe in mice infected with intermediate and high doses of adenovirus, and it was associated with more sustained induction of 2′5′-OAS, T-cell, and cytokine mRNAs in these animals (Fig. 1). Accordingly, HBV replication was inhibited for up to 6 weeks until the adenovirus infection resolved, and the T-cell and cytokine mRNAs disappeared from the liver, whereupon HBV replication resumed (Fig. 1).

HBV DNA replication occurs inside HBcAg-positive nucleocapsid particles in the cytoplasm of centrilobular hepatocytes in these transgenic mice (Fig. 2A) (21). HBV nucleocapsid particles are also detectable in the vast majority of hepatocyte nuclei in these animals (Fig. 2A), although these intranuclear core particles do not contain replicating viral genomes (21). After adenovirus infection, HBcAg disappeared from the cytoplasm of the centrilobular hepatocytes (Fig. 2C) with the same kinetics as the disappearance of HBV replicative DNA intermediates from the liver and circulating HBV DNA from the serum of these transgenic mice (not shown). It is noteworthy that only traces of β-galactosidase were detectable in the liver 1 day after low-dose Ad.CBlacZ infection, and only 2% of hepatocytes were β-galactosidase positive at the peak of disease on day 7, yet cytoplasmic HBV capsids and replicative forms disappeared from all of the centrilobular hepatocytes. These results indicate that suppression of HBV replication is not due to direct competition between adenovirus and HBV within the hepatocyte. Rather, the local induction of antiviral cytokines by the adenovirus infection is likely to mediate the observed effect. Interestingly, the intranuclear capsid antigen content was unaffected in these animals, consistent with the stability of hepatic HBV RNA content in most of the livers, as we will now discuss.
Adenovirus infection does not inhibit HBV gene expression in the livers of HBV transgenic mice. We have recently reported that adoptively transferred HBsAg-specific CTLs abolish HBV gene expression as well as HBV replication in the same lineage of transgenic mice (19). In addition, we have demonstrated that both HBV gene expression and replication are inhibited in the livers of transgenic mice during acute and chronic LCMV infection (16). As shown in Fig. 1A, however, the hepatic steady-state levels of the 3.5-kb pregenomic and 2.1-kb envelope HBV mRNAs were relatively unchanged in the livers of the adenovirus-infected HBV transgenic mice despite the induction of cytokines known to inhibit HBV gene expression following CTL injection or LCMV infection. These results indicate that HBV capsids and replicative intermediates are more susceptible to cytokine-induced inhibition than HBV RNA and that suppression of HBV replication is not due to a decrease in transcriptional template under these conditions.

MCMV infection inhibits HBV replication and gene expression in the livers of HBV transgenic mice. MCMV infects most visceral organs (36) and can cause acute hepatitis (43) in susceptible strains, including BALB/c and C57BL/6 (6, 14, 42). During acute MCMV infection, visceral lesions are induced both by the virus and by immunopathological mechanisms (15). In acutely infected mice, an early NK cell response (2, 4, 46) and a later CTL response (27) ultimately control the infection. To examine the effects of MCMV infection on hepatic HBV replication and gene expression, groups of matched transgenic mice were infected intraperitoneally with 2.0 × 10⁶ PFU of virulent salivary gland-passaged MCMV, and their livers were harvested on days 1, 3, 5, 7, and 14 after infection. By Southern blot analysis, total hepatic DNA was compared to DNA isolated from transgenic control animals receiving a salivary gland homogenate from uninfected mice.

As shown in Fig. 3, hepatic HBV replicative DNA forms were significantly reduced by the first day after MCMV infection in the absence of histological (not shown) and biochemical evidence of liver disease (sALT activity 18 U/l), indicating that it was not due to the destruction or turnover of hepatocytes. At this time point, 2.5'-OAS mRNA was detectable in the liver, while IFN-γ, TNF-α, and the T-cell markers were absent (Fig. 3). HBV DNA completely disappeared from the liver by the third day after infection. This was accompanied by moderately elevated sALT activity (340 U/liter), increased expression of 2.5'-OAS mRNA, and the induction of IFN-γ and TNF-α in the liver (Fig. 3) in the absence of T-cell markers, probably reflecting the presence of NK cells (32, 38) as well as the activation and recruitment of other inflammatory cells (e.g., Kupffer cells and monocytes). In contrast to adenovirus infection, MCMV profoundly suppressed the hepatic steady-state content of the 3.5- and 2.1-kb HBV mRNAs by the third day after infection (Fig. 3A), similar to the cytokine-mediated suppression of HBV gene expression and replication following CTL injection and LCMV infection (16). The reason why the same cytokines fail to inhibit hepatic HBV gene expression during adenovirus infection is currently unclear, especially since they were induced to comparable degrees in both infections (not shown) and for a much longer period of time during adenovirus infection (Fig. 1 and 3).

By day 5 after MCMV infection, T-cell markers (especially CD8) were strongly induced in the liver (Fig. 3), corresponding with further elevation of sALT activity (963 U/liter) and marking the beginning of an MCMV-specific T-cell response. Both HBV replication and HBV gene expression remained suppressed at this time, corresponding with the continued expression of all three cytokines (Fig. 3). The T-cell response continued at a reduced level on day 7, and the level of cytokine gene expression and the suppression of HBV gene expression were reduced to a commensurate degree. By day 14, MCMV was almost completely cleared from the liver and sALT activity, cytokines, and T-cell markers returned to baseline levels, as did the hepatic content of HBV DNA and HBV RNA. As in the adenovirus-infected animals, MCMV induced the disappearance of HBV nucleocapsids in the cytoplasm of the centrilobular hepatocytes (Fig. 2B) and virions from the serum (data not shown), with the same kinetics as that observed for the disappearance of HBV replicative DNA forms from the liver.

MCMV titers and liver pathology in MCMV-infected HBV transgenic mice. MCMV productively infects hepatocytes and replicates to high levels in the liver, reaching peak titers on day 3 after intraperitoneal infection (43). As expected, MCMV
titer in the liver (shown at the bottom of Fig. 3) peaked at 1.44 × 10^9 PFU/ml of tissue homogenate on the third day after infection. Surprisingly, this high level of hepatic MCMV replication was associated with only a slight elevation in sALT activity (340 U/liter). This finding indicates that direct viral damage to the liver was minimal at this time, suggesting that the profound reduction in HBV replication and gene expression observed in these livers was not the result of extensive hepatocyte destruction. This inference was confirmed by histological examination of the same livers on day 3 after MCMV infection, which showed small, scattered necroinflammatory foci containing infiltrating mononuclear cells and apoptotic hepatocytes (Fig. 2B, arrows) together with enlarged hepatocytes whose nuclei contained distinct intranuclear inclusions, indicative of MCMV replication. By day 5 postinfection, sALT activity rose to 963 U/liter, and widespread areas of inflammation containing mononuclear cells and necrotic and apoptotic hepatocytes were visible in the liver. At this time, MCMV titers in the liver fell more than 100-fold (134 PFU/ml of tissue homogenate), and T-cell markers and cytokine genes were strongly induced in the liver (Fig. 3), presumably reflecting the MCMV-specific cell-mediated immune response. By day 7, sALT activity dropped to 70 U/liter, the inflammatory foci were greatly reduced, and the MCMV titer remained low (112 PFU/ml of liver homogenate), suggesting that the MCMV infection was resolving. As expected, consistent with the diminished inflammatory response and reduced expression of antiviral cytokines, the level of HBV gene expression began to increase in the liver. By day 14, sALT activity was normal, only small and isolated inflammatory foci were visible in the liver, and cytokine and T-cell markers were barely detectable, at which point HBV DNA and HBV RNA returned to preinfection levels.

MCMV infects the kidney and inhibits renal HBV replication and gene expression, but adenovirus does not. HBV replicates to high levels in the proximal convoluted tubules of the kidney in these transgenic mice as well as in the liver (21). In a recent study, we showed that interleukin-12 can abolish HBV replication in the kidney as well as in the liver in similar transgenic mice (5). To examine the effects of adenovirus and MCMV infections on renal HBV replication and gene expression, the kidneys of transgenic mice infected with Ad.CBlacZ or MCMV were analyzed as described above.

In this analysis, we found that MCMV productively infects the kidney, where, by day 5, it induces a mild interstitial inflammatory infiltrate composed of IFN-γ and TNF-α-producing T cells (not shown). This inflammatory infiltrate became more prominent by day 7 after infection, and renal inflammation at this time consisted of a glomerular as well as an interstitial nephritis. As early as day 3, however, HBV DNA replicative forms and cytoplasmic HBcAg were eliminated from the kidney (Fig. 2F and 4) in the absence of histological evidence of kidney disease. Also on day 3, HBV DNA and cytoplasmic HBcAg disappeared from the livers of the same animals; however, this suppression occurred in the presence of liver disease (described above). MCMV titers peaked in both tissues by day 3 after infection (1.44 × 10^9 PFU/ml of liver homogenate; 3.75 × 10^8 PFU/ml of kidney homogenate), and mRNAs encoding 2′5′-OAS (Fig. 3 and 4), TNF-α, and IFN-γ (Fig. 3 and data not shown for kidney) were detectable in both tissues. In addition, the steady-state content of HBV RNA was dramatically reduced in the liver (Fig. 3) at this time point but was only slightly reduced in the kidney (data not shown). Histologically, there was no evidence of inflammation in the kidneys until the fifth day after infection, when T-cell markers were first detectable and interstitial nephritis was evident. At this time, renal HBV RNA content was further reduced (not shown), and renal MCMV titers dropped to 1.73 × 10^3 PFU/ml, marking the onset of the T-cell-mediated immune response in the kidney. Also as in the liver, HBV replication and gene expression were suppressed in the kidney from days 3 to 7 postinfection, returning to baseline levels by day 14, when the cytokine genes and T-cell markers were no longer detectable in the kidney and the MCMV infection was cleared from this tissue (13 PFU/ml).

In contrast to MCMV, the kidney is not readily infected by Ad.CBlacZ since only the glomeruli were β-galactosidase positive (Fig. 2H) whereas nearly all of the hepatocytes were positive (Fig. 2D). To determine if glomerular infection is sufficient to inhibit HBV replication in the tubular epithelial cells, total cellular DNA was extracted from the kidney and Southern blot analysis was performed (Fig. 4). Although HBV replication was profoundly suppressed in the livers of these mice (Fig. 1), there was little change in HBV replication in the kidney (Fig. 4). Consistent with these results, there were no changes in cytoplasmic HBcAg in the proximal convoluted tubules of the kidney, no histological evidence of inflammation in the kidneys of the adenovirus-infected mice (Fig. 2G), and only minimal expression of 2′5′-OAS (Fig. 4), TNF-α, IFN-γ, or the T-cell marker mRNAs (data not shown). These results reflect the fact that the kidney is not readily infected by this recombinant adenovirus.

Early suppression of HBV replication by adenovirus and MCMV is mediated by IFN-α/β and TNF-α. Since IFN-α/β and TNF-α mRNAs were detectable in the liver within 1 day after adenovirus (Fig. 1) and MCMV (Fig. 3) infections, we monitored the ability of neutralizing antibodies to these cytokines to modulate HBV replication and the expression of 2′5′-OAS mRNA 24 h after infection. Groups of age- and sex-matched transgenic mice were injected intraperitoneally with a mixture of sheep antiserum against murine IFN-α/β (13) and MAb against murine TNF-α (44) 6 h before infection with either 1.5 × 10^9 PFU of Ad.CBlacZ or 5.0 × 10^8 PFU of MCMV. Control mice were injected with a mixture of irrele-
mice were intraperitoneally injected with a combination of antibodies to IFN-α/β and TNF-α. Groups of three HBV transgenic mice were intraperitoneally injected with a combination of antibodies to IFN-α/β and TNF-α or with control antibodies 6 h before infection with 5.0 × 10⁹ PFU of MCMV or 1.5 × 10⁹ PFU of Ad.CBlacZ and were sacrificed 24 h after infection. Total hepatic DNA and RNA were extracted, analyzed by Southern and Northern blotting, respectively, for the expression of HBV DNA replicative forms and 3'–OAS mRNA, and compared with total hepatic DNA and RNA from two saline-injected control mice (lanes NaCl). Southern (A) and Northern (B) blot analyses were performed exactly as described in the legend to Fig. 1 for two representative mice per group. Abbreviations are as defined in the legend to Fig. 1.

FIG. 5. Early suppression of HBV replication by adenovirus and MCMV infections is mediated by IFN-α/β and TNF-α. Groups of three HBV transgenic mice were intraperitoneally injected with a combination of antibodies to IFN-α/β and TNF-α or with control antibodies 6 h before infection with 5.0 × 10⁹ PFU of MCMV or 1.5 × 10⁹ PFU of Ad.CBlacZ and were sacrificed 24 h after infection. Total hepatic DNA and RNA were extracted, analyzed by Southern and Northern blotting, respectively, for the expression of HBV DNA replicative forms and 3'–OAS mRNA, and compared with total hepatic DNA and RNA from two saline-injected control mice (lanes NaCl). Southern (A) and Northern (B) blot analyses were performed exactly as described in the legend to Fig. 1 for two representative mice per group. Abbreviations are as defined in the legend to Fig. 1.

**DISCUSSION**

In this study, we demonstrate that inflammatory cytokines induced during adenovirus and cytomegalovirus infection suppress HBV replication in two distinct waves in infected tissues. The first wave occurs during the first 24 h of infection and is characterized by the disappearance of cytoplasmic HBV nucleocapsids and replicative DNA intermediates in response to the antiviral effects of IFN-α/β induced by the infecting virus. Since there is no liver disease or hepatocellular regeneration at this time point, the antiviral effect cannot be ascribed to the lysis or turnover of infected cells. The second wave is mediated by IFN-α/β, IFN-γ, and TNF-α produced during the cellular immune response to each virus, beginning between 3 to 5 days after infection and continuing until the incoming virus is cleared. Since tissue injury is evident during this period, theoretically the inhibition of HBV gene expression and replication observed at these time points could be due, at least in part, to the destruction and regeneration of HBV-positive hepatocytes. This is unlikely, however, because we have previously reported that HBV gene expression and replication are not suppressed during hepatocyte turnover, provided that certain cytokines are absent (18).

These observations extend our understanding of the host-virus relationship during HBV infection at several important levels. For example, this is the first report that HBV gene expression and replication can be inhibited by hepatocytotropic DNA viruses, like HBV, providing additional support to the notion that similar antiviral events can limit HBV infection during acute viral hepatitis in humans. Next, this is the first demonstration of the biphasic nature of the antiviral effect of a hepatotrophic viral infection, emphasizing the importance of the initial, nonspecific, innate response to infection. Furthermore, this report provides the first evidence that certain viruses can inhibit HBV replication in tissues other than the liver. Specifically, we showed that HBV replication is suppressed in the kidney during MCMV infection but not during adenovirus infection, apparently because MCMV infects the kidney much more efficiently than adenovirus. Finally, this report illustrates that HBV replication is more sensitive to cytokine-mediated control than HBV gene expression. Furthermore, since HBV gene expression is inhibited during MCMV infection but not during adenovirus infection, even though IFN-α/β, TNF-α, and IFN-γ are induced to comparable degrees for similar periods of time in both infections, the present data suggest that these cytokines may be necessary but not sufficient to eliminate HBV RNA from the liver. Rather, the data are consistent with a model in which the inhibition of HBV RNA expression is mediated by two independent but parallel mechanisms: one induced by IFN-α/β, TNF-α, and IFN-γ, and the other induced by an unknown factor or factors. According to this model, both pathways must be induced to inhibit HBV gene expression. If this is correct, it is possible that MCMV infection induces both pathways whereas adenovirus infection induces only the first. Alternatively, it is theoretically possible that the two viruses can trigger both pathways, with adenovirus infection also inducing a third pathway that inhibits one of the others.

Since the inflammatory disease induced by both of these viruses is histologically similar to viral hepatitis in humans, and because of the extraordinary efficiency of these antiviral processes, the present data suggest that inflammatory cytokines can contribute to viral clearance during acute HBV infection. In view of these results, it is interesting that HBV infection has been shown to resolve during hepatitis A virus (8) and hepatitis C virus (45) superinfection of chronic HBV carriers, perhaps by a process similar to that described herein. The failure of these mechanisms to clear HBV in chronically infected patients may be due to the relative mildness of the inflammatory response in those individuals (7). Alternatively, the quality of the intrahepatic cytokine profile may differ during acute and chronic hepatitis. This curative intracellular viral inactivation process may greatly amplify the protective effects of the immune response and may be particularly important in massive infections of vital organs where the host must eliminate the infecting virus while preserving the tissue. The intracellular viral inactivation pathways that are responsible for this remarkable effect are undefined.

These observations raise the possibility that inflammatory cytokines contribute to the control of other viral infections. For example, during MCMV infection, IFN-γ and TNF-α are thought to be required to clear virus from persistently infected salivary glands (30, 33) and dramatically alter the morphogenesis of MCMV nucleocapsids, profoundly reducing virus replication (29). Indeed, neutralization of IFN-α/β, IFN-γ, or TNF-α during MCMV infection results in a significant increase in virus burden in several organs, including the liver (23, 31). TNF-α has also been reported to inhibit the replication of adenovirus, and IFN-γ synergizes with TNF-α to further reduce viral replication (53). In addition, IFN-α/β, IFN-γ, and TNF-α have also been shown to control other viral infections in vivo, including lymphocytic choriomeningitis virus (34), vac-
cinia virus (26, 39, 51), measles virus (10), herpes simplex virus (3, 37), influenza virus (49), and mouse hepatitis virus (61). The mechanisms responsible for the antiviral effects of these cytokines are not well defined, however, and they may do so primarily by facilitating development of the immune response against these infections rather than by exerting a direct antiviral effect on virus replication in these systems. Further studies are needed to clarify this important issue.

In keeping with the concept of intracellular viral inactivation, a number of viruses encode proteins that have the potential to inhibit the antiviral actions of interferons (11), including adenovirus, where the EIA proteins block the activation of interferon response genes by inhibiting the function of a cellular transcription factor (ISGF3) that is activated when IFN-α/β binds to its receptor (22, 25, 35). Viruses may also have evolved additional strategies for circumventing host antiviral defenses by encoding receptor analogues for IFN-αβ, IFN-γ, and TNF-α (1, 40, 48), thereby neutralizing the antiviral activity of these cytokines. In fact, adenoviruses encode three proteins (E3-14.7K, E3-10.4K/14.5K, and E1B-19K) that protect the infected cell against the antiviral effects of TNF-α (52). At present, none of the seven proteins encoded by the HBV genome (precore, core, polymerase, large envelope, middle envelope, major envelope, and X proteins) have been shown to block the antiviral actions of host cytokines.

It is possible, therefore, that the curative properties of inflammatory cytokines produced by virus-specific T cells, NK cells, and macrophages play a pivotal role in the outcome of many viral infections in addition to HBV. If this concept is correct, it is likely that each virus will exhibit its own individual cytokine sensitivity profile, and some viruses may resist cytokine-mediated control. Future analysis of the molecular basis for viral sensitivity and resistance to cytokine-mediated control is clearly warranted, not only to provide better insight into the immunopathogenesis of these viral infections but also to facilitate the development of therapeutic strategies to deliver or induce the appropriate antiviral cytokines in infected tissue.

ACKNOWLEDGMENTS

We thank James Wilson for providing the recombinant adenovirus Ad.CBla2Z; Ann Campbell for providing the hamster MAb to murine IFN-α/β, IFN-γ, and TNF-α; and Jennifer Newmann and Pamela Fagan for help with manuscript preparation. This work was supported by grants R37 CA40489 and AI40696 from the National Institutes of Health.

REFERENCES

13. Greber, U. G., J. S. Mackenzie, and N. F. Stanley. 1993. Patterns of cytokine gene expression by CD4+ T cells, NK cells, and macrophages play a pivotal role in the outcome of many viral infections in addition to HBV. If this concept is correct, it is likely that each virus will exhibit its own individual cytokine sensitivity profile, and some viruses may resist cytokine-mediated control. Future analysis of the molecular basis for viral sensitivity and resistance to cytokine-mediated control is clearly warranted, not only to provide better insight into the immunopathogenesis of these viral infections but also to facilitate the development of therapeutic strategies to deliver or induce the appropriate antiviral cytokines in infected tissue.


